China considers mixing of COVID-19 vaccines due to their low efficacy rate

While the vaccine requires less stringent temperature controls, available data shows that the Chinese vaccines lag behind others including Pfizer and Moderna.

Advertisement

The director of the Chinese Center For Disease Control And Prevention Mr. Gao Fu, spoke about the vaccines at a conference held recently. He said, “The currently available vaccines do not have very high rates of protection. Inoculation using vaccines of different technical lines is being considered.”

China has developed four domestic vaccines approved for public use. An official source told that China will likely produce 3 billion doses by the end of this year.

Meanwhile, Mr Gao said that a definite solution to efficacy issues was to “optimise” the vaccine delivery process, including changing the number of doses and increasing the length between two consecutive doses. China’s Sinovac has developed a COVID-19 vaccine which was found to have an efficacy rate of 50% in Brazilian clinical trials and 83.5%  in a study conducted in Turkey.

As of now, no detailed efficacy data has been released by China’s Sinopharm. Although, it has claimed that the two vaccines developed by its units are 79.4% and 72.5% effective respectively.

 

A World Health Organisation (WHO) panel in March said that both the vaccines makers have presented data on their efficacy levels that are in line with those required by WHO. Meanwhile, Chinese officials and state media are vehemently defending the vaccine shots produced in China and questioned the safety and logistical capabilities of other vaccines.